Funding Support and Author Disclosures This study was supported by national funds through Fundação para a Ciência e a Tecnologia, I.P., under the scope of the Cardiovascular R&D Center-Cardiovascular R&D Unit (UIDB/00051/2020 and UIDP/00051/2020). Dr Neves has received consulting or speaker fees from AstraZeneca, BIAL, Boehringer Ingelheim, Lilly, Merck, and Novo Nordisk. Dr Borges Canha has received speaker fees from AstraZeneca and Medinfar. Dr Green has received institutional grant funding from Boehringer Ingelheim–Lilly, Merck, Roche, and Sanofi and Lexicon; and has received consultancy fees from Boehringer Ingelheim–Lilly, Bayer, AstraZeneca, Sanofi and Lexicon, Hawthorne Effect and Omada, Pfizer, Valo, Anji, Vertex, and Novo Nordisk. Dr Leiter has received research funding from, has provided continuing medical education on behalf of, and/or has acted as an advisor to AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Lexicon, Merck, Novo Nordisk, Pfizer, Sanofi, and Servier. Dr Granger has received research grants from AKROS, Apple, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Duke Clinical Research Institute, the U.S. Food and Drug Administration, GlaxoSmithKline, Janssen Pharmaceutical Products, LP, Medtronic Foundation, Novartis Pharmaceuticals, and Pfizer; and has received consulting fees from AbbVie, Abiomed, Anthos Therapeutic, LLC, Bayer Corporation, Boehringer Ingelheim, Boston Scientific Corporation, Bristol Myers Squibb, CeleCor Therapeutics, Correvio, Espero BioPharma, Janssen Pharmaceutica Products, LP, Medscape, LLC, Medtronic Inc, Merck, Novo Nordisk, Novartis Pharmaceutical Company, Pfizer, Phillips, Rhoshan Pharmaceuticals, and Roche Diagnostics. Dr Carvalho has received consulting or speaker fees from AstraZeneca, BIAL, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck, Merck Co, Medinfar, Novo Nordisk, and Sanofi. Dr Hernandez has received grants from Amgen, Bayer, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Pfizer and Verily; and has received consulting fees from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis Pharmaceuticals, and Novo Nordisk. Dr Del Prato has received grants from AstraZeneca and Boehringer Ingelheim; has received consulting fees from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Hengrui Pharmaceuticals Co, Menarini International, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk, and Sanofi; and has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk, and Sanofi. Dr McMurray has received institutional grant funding from AstraZeneca; has received consultancy fees from Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Lupin, Sun Pharmaceuticals, Heart.Org (Medscape Cardiology), ProAdWise Communications, Radcliffe Cardiology, Servier, and The Corpus; and has received fees paid to his institution for other advisory roles by Cytokinetics, Amgen, AstraZeneca, Theracos, Ionis Pharmaceuticals, DalCor, Cardurion, Novartis, GlaxoSmithKline, Bayer, KBP Biosciences, Boehringer Ingelheim, and Bristol Myers Squibb. Dr Ferreira is a consultant for Boehringer Ingelheim; and has received research support from AstraZeneca and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PubMed
